Drug recall · January 21, 2026
Clindamycin Phosphate USP recall
Why: Failed Impurities/Degradation: Out of Specification results for Total Impurities and for Assay.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Clindamycin Phosphate USP, 1% (10 mg/mL), Topical Solution, 60 mL per applicator bottle, Rx only, Mfd. by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel; Dist. by: Taro Pharmaceuticals USA, Inc., Hawthorne, NY 10532, NDC# 51672-4081-4
- Lots / codes
Lot#: AD30154, AD31143, AD31145, Exp 11/30/2025
- Company
- Sun Pharmaceutical Industries Inc, Princeton, NJ
- Distribution
- Nationwide in the USA.
- Initiated
- November 26, 2025 · Voluntary: Firm initiated
- Classified
- January 14, 2026
- Reported
- January 21, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Clindamycin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.